Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.33 |
| ▸ | THRA | P10827 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.32 |
| ▸ | HTR1B | P28222 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12889169 | 1.00 | PDE2A (0.33) | PDE2ATHRATHRBCRBNTSHR | |
| SCHEMBL10301845 | 1.00 | PDE2A (0.33) | PDE2ATHRATHRBCRBNTSHR | |
| SCHEMBL10301843 | 0.99 | CRBN (0.34) | PDE2ATHRATHRBCRBNTSHR | |
| SCHEMBL10301842 | 0.97 | CRBN (0.35) | PDE2ACRBNACACBTLR4TLR2 | |
| SCHEMBL12734182 | 0.90 | HRH3 (0.34) | PDE2ATHRATHRBCRBNTSHR | |
| SCHEMBL12734179 | 0.90 | HRH3 (0.34) | PDE2ATHRATHRBCRBNTSHR | |
| SCHEMBL12734185 | 0.90 | HRH3 (0.34) | PDE2ATHRATHRBCRBNTSHR | |
| SCHEMBL10301841 | 0.89 | HPGD (0.32) | THRBTSHR | |
| SCHEMBL12734169 | 0.89 | CRBN (0.33) | PDE2ACRBNTSHRCNR2CNR1 | |
| SCHEMBL10301849 | 0.88 | MAPT (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | PDE2A 3397/4885THRA 2022/4885THRB 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.